| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8714082 | The Journal of Allergy and Clinical Immunology: In Practice | 2018 | 35 Pages |
Abstract
Omalizumab provided clinical benefits in approximately 80% of patients with SU. Patients failing to improve on standard omalizumab doses may benefit from higher monthly dosages.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Igor MD, Noa MD, Moshe MD, MPH, Claes David MD, PhD, Yuval MD, PhD, Yossi MD, Ronit MD, Emmilia MD, Assi MD,